Geographical distribution of clinical trials in amyotrophic lateral sclerosis: a scoping review.
Amyotroph Lateral Scler Frontotemporal Degener
; 25(3-4): 376-381, 2024 May.
Article
em En
| MEDLINE
| ID: mdl-38393299
ABSTRACT
Introduction:
Clinical trials location is determined by many factors, including the availability of patient populations, regulatory environment, scientific expertise, and cost considerations. In clinical drug development of amyotrophic lateral sclerosis (ALS), where genetic differences have been described and may be related to geographic setting, this could have implications for the clinical interpretation of results in underrepresented geographic settings.Objective:
The aim of this study was to review country participation in ALS clinical research based on available data from clinical trial registries and databases.Methods:
We performed a scoping review with available information about clinical trials on ALS in ClinicalTrials.gov (CT), EU clinical trials register (EudraCT), WHO International Clinical Trials Registry Platform (ICTRP) and Web of Science (WOS). Inclusion criteria were clinical trials in phase 2 and 3 to treat ALS, recruiting or active not recruiting, from 23/06/2018 to 23/06/2023.Results:
The total number of clinical trials identified were 188; 54 studies in CT, 38 in EudraCT, 47 in ICTRP and 49 in WOS. We identified 77 clinical trials after deleting duplicates and applying exclusion criteria. The countries with most studies conducted were the US with 35 studies (10.9%), followed by the United Kingdom, Belgium, France and Germany with 21 studies each one of them (6.5%).Conclusion:
The data obtained in our review showed a non-homogeneous distribution in clinical trials at the international level, which may influence the interpretation of the results obtained.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Esclerose Lateral Amiotrófica
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article